Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 138, Issue 5, Pages 1129-1138Publisher
WILEY
DOI: 10.1002/ijc.29853
Keywords
hemoglobin adduct; acrylamide; glycidamide; endometrial cancer; EPIC
Categories
Funding
- Wereld Kanker Onderzoek Fonds (WCRF NL) [WCRF 2011/442]
- Health Research Fund (FIS) of the Spanish Ministry of Health [PI11/01473]
- Navarra and the Catalan Institute of Oncology, La Caixa [BM 06-130]
- Red Tematica de Investigacion Cooperativa en Cancer (Spain) [RD12/0036/0018, RD06/0020/0091]
- European Commission (DG-SANCO)
- International Agency for Research on Cancer
- Danish Cancer Society (Denmark)
- Ligue contre le Cancer
- Institut Gustave Roussy
- Mutuelle Generale de l'Education Nationale
- Institut National de la Sante et de la Recherche Medicale (INSERM) (France)
- Deutsche Krebshilfe
- Deutsches Krebsforschungszentrum (DKFZ)
- Federal Ministry of Education and Research (Germany)
- Hellenic Health Foundation (Greece)
- Associazione Italiana per la Ricerca sul Cancro (AIRC)
- National Research Council (Italy)
- Dutch Ministry of Public Health, Welfare and Sports (VWS)
- Netherlands Cancer Registry (NKR)
- LK Research Funds
- Dutch Prevention Funds
- Dutch ZON (Zorg Onderzoek Nederland)
- World Cancer Research Fund (WCRF)
- Statistics Netherlands (The Netherlands)
- Nordic Center of Excellence in Food, Nutrition and Health Helga (Norway)
- Swedish Cancer Society
- Swedish Scientific Council and Regional Government of Skane and Vasterbotten (Sweden)
- Cancer Research UK
- Medical Research Council (United Kingdom)
- Health Research Fund (FIS) of the Spanish Ministry of Health, Regional Government of Andalucia [6236]
- Health Research Fund (FIS) of the Spanish Ministry of Health, Regional Government of Asturias [6236]
- Health Research Fund (FIS) of the Spanish Ministry of Health, Regional Government of Basque Country [6236]
- Health Research Fund (FIS) of the Spanish Ministry of Health, Regional Government of Murcia [6236]
- Cancer Research UK [14136, 16491] Funding Source: researchfish
- Medical Research Council [G0401527, MC_UU_12015/1, G1000143, MC_U106179471] Funding Source: researchfish
- National Institute for Health Research [NF-SI-0512-10114, NF-SI-0512-10135] Funding Source: researchfish
- MRC [MC_UU_12015/1] Funding Source: UKRI
Ask authors/readers for more resources
Acrylamide, classified in 1994 by IARC as probably carcinogenic to humans, was discovered in 2002 in some heat-treated, carbohydrate-rich foods. Four prospective studies have evaluated the association between dietary acrylamide intake and endometrial cancer (EC) risk with inconsistent results. The purpose of this nested case-control study, based on the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, was to evaluate, for the first time, the association between hemoglobin adducts of acrylamide (HbAA) and glycidamide (HbGA) and the risk of developing EC in non-smoking postmenopausal women. Hemoglobin adducts were measured in red blood cells by HPLC/MS/MS. Four exposure variables were evaluated: HbAA, HbGA, their sum (HbAA1HbGA), and their ratio (HbGA/HbAA). The association between hemoglobin adducts and EC was evaluated using unconditional multivariable logistic regression models, and included 383 EC cases (171 were type-I EC), and 385 controls. Exposure variables were analyzed in quintiles based on control distributions. None of the biomarker variables had an effect on overall EC (HRHbAA;Q5vsQ1: 0.84, 95% CI: 0.49-1.48; HRHbGA;Q5vsQ1: 0.94, 95% CI: 0.54-1.63) or type-I EC risk. Additionally, none of the subgroups investigated (BMI < 25 vs. >= 25 kg m 22, alcohol drinkers vs. never drinkers, oral contraceptive users vs. non-users) demonstrated effect measure modification. Hemoglobin adducts of acrylamide or glycidamide were not associated with EC or type-I EC risk in 768 nonsmoking postmenopausal women from the EPIC cohort.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available